| Exogenous Glucagon-Like Peptide-1 for Hyperglycemia in Critically Ill Patients (January). | |
| | |
MedLine Citation:
|
PMID: 22202493 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE:To review literature evaluating the safety and efficacy of exogenous glucagon-like peptide-1 (GLP-1) for hyperglycemia in critically ill patients.DATA SOURCES:PubMed was queried (inception to September 3, 2011), using the search term glucagon-like peptide-1. The search was limited to studies published in English and conducted in humans. Regular and late-breaking abstracts from the American Diabetes Association Scientific Sessions in 2009 and 2010 were also searched using the same search term.STUDY SELECTION AND DATA EXTRACTION:All abstracts were screened for eligibility, which consisted of studies reporting the effects of intravenous GLP-1 administration on glycemic control in critically ill patients. Data extracted from eligible trials included study and population characteristics, measures of glycemic efficacy, and safety.DATA SYNTHESIS:Our search resulted in the identification of 2105 potentially relevant articles; of those, 7 were reviewed. All included publications evaluated the use of intravenous GLP-1 (1.2-3.6 pmol/kg/min) compared with insulin or placebo infused for 4.5-72 hours in critically ill patients. The majority (n = 4) of studies included only patients from a surgical intensive care setting, and 71% (n = 5) of trials included those with a history of diabetes. Relative to insulin or placebo, GLP-1 therapy effectively lowered blood glucose concentrations in all trials. Out of 81 total study participants receiving GLP-1, only 4 had documentedhypoglycemia (<60 mg/dL), 4 reported nausea, and 2 experienced vomiting. No other serious adverse events were reported.CONCLUSIONS:All trials reviewed suggest that GLP-1 may be a promising agent for the management of hyperglycemia in critically ill patients, regardless of diabetes status. Additional studies in more heterogeneous intensive care settings comparing GLP-1 with insulin, the current standard of care, are necessary. These studies should evaluate long-term safety and effectiveness of GLP-1 therapy on morbidity and mortality outcomes in critically ill populations. |
| | |
Authors:
|
Nicole R Pinelli; Mathew C Jones; Lea M Monday; Zachary Smith; Denise H Rhoney |
Related Documents
:
|
339033 - Diabetic microangiopathy. i. current status of the chemistry and metabolism of the glom... 9360013 - Contrast media induced changes in tubular electrophysiology and glomerular filtration r... 20622173 - Fetal exposure to maternal type 1 diabetes is associated with renal dysfunction at adul... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-27 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: - ISSN: 1542-6270 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
< Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migr...
Next Document: Use of Topical Tranexamic Acid or Aminocaproic Acid to Prevent Bleeding After Major Surgical Proce...